Jeremy Grantham's NVO Position Overview
Jeremy Grantham (via Grantham, Mayo, Van Otterloo & Co. LLC) currently holds 184,971 shares of Novo Nordisk A/S (NVO) worth $9.41 M, representing 0.02% of the portfolio. First purchased in 2016-Q1, this medium-term investment has been held for 15 quarters.
Based on 13F filings, Jeremy Grantham has maintained a strategic position in NVO, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2018, adding 1.31 M shares. Largest reduction occurred in Q3 2019, reducing 1.47 M shares.
Analysis based on 13F filings available since 2013 Q2
Jeremy Grantham's Novo Nordisk A/S (NVO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Novo Nordisk A/S (NVO) Trades by Jeremy Grantham
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +108,359 | Add 141.44% | 184,971 | $50.88 |
| Q3 2025 | +15,027 | Add 24.40% | 76,612 | $55.49 |
| Q2 2025 | +23,968 | Add 63.72% | 61,585 | $69.02 |
| Q1 2025 | +37,617 | New Buy | 37,617 | $69.44 |
| Q3 2019 | -1.47 M | Sold Out | 0 | $0.00 |
| Q2 2019 | -887,200 | Reduce 37.70% | 1.47 M | $25.52 |
| Q1 2019 | +351,600 | Add 17.56% | 2.35 M | $26.15 |
| Q4 2018 | +34,200 | Add 1.74% | 2 M | $23.03 |
| Q3 2018 | +604,706 | Add 44.36% | 1.97 M | $23.57 |
| Q2 2018 | +49,054 | Add 3.73% | 1.36 M | $23.06 |
| Q1 2018 | +1.31 M | New Buy | 1.31 M | $24.62 |
| Q4 2016 | -123,400 | Sold Out | 0 | $0.00 |
| Q3 2016 | -51,800 | Reduce 29.57% | 123,400 | $20.79 |
| Q2 2016 | -70,000 | Reduce 28.55% | 175,200 | $26.89 |
| Q1 2016 | +245,200 | New Buy | 245,200 | $27.10 |
Jeremy Grantham's Novo Nordisk A/S Investment FAQs
Jeremy Grantham first purchased Novo Nordisk A/S (NVO) in Q1 2016, acquiring 245,200 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jeremy Grantham has held Novo Nordisk A/S (NVO) for 15 quarters since Q1 2016.
Jeremy Grantham's largest addition to Novo Nordisk A/S (NVO) was in Q1 2018, adding 1,314,000 shares worth $32.36 M.
According to the latest 13F filing for Q4 2025, Jeremy Grantham's firm, Grantham, Mayo, Van Otterloo & Co. LLC, owns 184,971 shares of Novo Nordisk A/S (NVO), valued at approximately $9.41 M.
As of the Q4 2025 filing, Novo Nordisk A/S (NVO) represents approximately 0.02% of Jeremy Grantham's publicly disclosed stock portfolio, making it one of their key holdings.
Jeremy Grantham's peak holding in Novo Nordisk A/S (NVO) was 2,353,560 shares, as reported at the end of Q1 2019.